NEW_CURA-LEAF_1170x120_OCT

Rob Koremans

Teva unveils reorganization plan

Teva unveils reorganization plan

  JERUSALEM, Israel — Just over two months after naming a new chief executive officer, Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, is reorganizing its business and leadership structure. Teva said Monday that it’s integrating its drug businesses into one commercial organization, and there will no longer be two separate global

Teva gets FDA’s OK for Vantrela ER

Teva gets FDA’s OK for Vantrela ER

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has received Food and Drug Administration approval for Vantrela ER, an opioid pain medication with Teva’s abuse deterrence technology. Vantrela ER (hydrocodone bitartrate extended-release tablets, CII) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which other treatment options